Kindbody is a technology company.
Kindbody has raised $123.0M across 5 funding rounds.
Kindbody has raised $123.0M in total across 5 funding rounds.
Kindbody has raised $123.0M in total across 5 funding rounds.
Kindbody's investors include Adverb Ventures, Greylock, GV, Erel Margalit, LAUNCH, Offline Ventures, Otherwise Fund, RRE Ventures, Spark Capital, Upfront Ventures, VSC Ventures, Dennis Crowley.
Kindbody is a leading fertility clinic network and family-building benefits provider that operates tech-enabled clinics offering comprehensive reproductive healthcare services. It builds proprietary technology like the HIPAA-compliant KindEMR electronic medical record system, which standardizes care, enables online scheduling, virtual/in-person appointments, and an intuitive patient portal covering fertility assessments, IVF, egg freezing, genetic testing, donor/surrogacy services, adoption, postpartum care, and menopause support.[1][2][5][6] Kindbody serves patients directly at 35+ signature clinics and IVF labs, 400+ partner clinics across 113 countries, and provides employer benefits to over 133 companies covering millions of lives, solving accessibility, affordability, and fragmentation issues in fertility care by integrating clinics, technology, and benefits for superior outcomes at lower costs.[1][2]
The company targets individuals and couples pursuing family-building regardless of sex, orientation, or marital status, as well as employers seeking comprehensive benefits. It addresses high costs, stigma, lack of transparency, and inefficient care through vertical integration, AI enhancements, and patient-centric design, evidenced by rapid growth: ranked No. 72 on the 2024 Deloitte Technology Fast 500 and No. 30 in 2023.[1][2]
Kindbody was founded in 2018 by Gina Bartasi, who aimed to transform fertility care by making it more intuitive, empowering, and less daunting amid a fragmented healthcare system.[2][6] Bartasi envisioned vertical integration—combining clinics, technology, and employer benefits—after recognizing gaps in patient access, concierge services, and end-to-end support like mobile blood tests and IVF hand-holding.[3][6] Early traction came from its physician-led model and tech investments, quickly establishing it as the only provider owning and operating clinics while serving employers.[1][2] Pivotal moments include launching KindEMR for full-spectrum care standardization and expanding to dozens of clinics, earning Deloitte Fast 500 recognitions by 2023-2024 for explosive revenue growth.[1][2]
Kindbody rides the fertility tech wave, blending healthcare with AI, automation, and consumer-friendly design amid rising demand for family-building amid delayed parenthood, infertility rates, and employer benefits expansion.[1][3][5] Timing aligns with post-2018 shifts: Modern Fertility's at-home testing and apps like Natural Cycles popularized transparent data ownership, while Kindbody vertically integrates to offer end-to-end solutions beyond niche tools.[3] Market forces favoring it include employer mandates for fertility coverage, AI advancements in repro medicine (e.g., embryo selection), and verticalization trends for better outcomes/costs; it influences the ecosystem by setting standards for clinic-owned tech-benefits hybrids, partnering on R&D, and accelerating accessible precision fertility care globally.[1][2][4]
Kindbody's momentum positions it to dominate as fertility tech matures, with AI-driven personalization, cryo-automation, and global expansion likely driving further growth beyond Deloitte rankings.[1][4] Trends like AI precision medicine, employer benefits normalization, and holistic repro health (preconception to menopause) will shape its path, potentially through more acquisitions or tech licensing.[2][5] Its influence may evolve from disruptor to industry leader, redefining scalable family-building—echoing its mission to make fertility affordable and accessible for all, starting from Gina Bartasi's vision of empowered care.[6]
Kindbody has raised $123.0M across 5 funding rounds. Most recently, it raised $62.0M Series C in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $62.0M Series C | Adverb Ventures, Greylock, GV, Erel Margalit, LAUNCH, Offline Ventures, Otherwise Fund, RRE Ventures, Spark Capital, Upfront Ventures, VSC Ventures, Dennis Crowley, Scott Belsky | |
| Jul 1, 2020 | $32.0M Series B | ACME Capital, Brainchild, Distributed Ventures, GV, Erel Margalit, KRM Interests LLC, RRE Ventures, SuperAngel.Fund, Upfront Ventures, VSC Ventures, Baron Davis, Demi Lovato, Shervin Pishevar | |
| Dec 1, 2019 | $10.0M Series A | GV, Erel Margalit, RRE Ventures, Upfront Ventures, VSC Ventures | |
| Apr 1, 2019 | $15.0M Series A | Kindred Ventures, Samsung NEXT Ventures, SLVC, William Mougayar | |
| Jul 1, 2018 | $4.0M Seed | Bloomberg Beta, Clearvision Ventures, Curie.Bio, General Catalyst, Maverick Capital, Operator Partners, Redpoint Ventures, Rock Health, Sequoia Capital, TCG (The Chernin Group), Tiger Global Management, TMV, Town Hall Ventures, Halle Tecco, Jeff Hammerbacher, Vivek Garipalli |